Agomab Spain S.L.U. clinical trials
Acquired by Agomab Therapeutics NV, Dec 14, 2021 · source ↗
The registry lists 5 studies whose lead sponsor is Agomab Spain S.L.U. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 19, 2026.
- 5studies on the registry
- 3open to participants now
- 1reach primary completion within a year
Before and after it joined Agomab Therapeutics NV
- First submitted before Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- 0
- First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- 5
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Agomab Spain S.L.U.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
1 of Agomab Spain S.L.U.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
- Jan 2027Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteersontunisertib · NCT07672574
Add it to your calendar (.ics) → With an account.
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Agomab Spain S.L.U.5 studies
Something wrong with this grouping? Tell us on the Agomab Therapeutics NV page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Agomab Therapeutics NV studies →
- Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersRecruitingNCT07672574Phase 1
Sponsor listed in the registry: Agomab Spain S.L.U. · First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseaseRecruitingNCT07683325Phase 2
Sponsor listed in the registry: Agomab Spain S.L.U. · First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- A Trial of AGMB-447 in Participants With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07862634Phase 2
Sponsor listed in the registry: Agomab Spain S.L.U. · First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseCompletedNCT05843578Phase 2
Sponsor listed in the registry: Agomab Spain S.L.U. · First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV
- A Multiple Ascending Dose Study With AGMB-129 in Healthy ParticipantsCompletedNCT07118878Phase 1
Sponsor listed in the registry: Agomab Spain S.L.U. · First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV